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ABSTRACT 
Introduction: For many years, stress and anxiety disorders have taken a heavy toll on 
the American population. Affecting approximately 40 million individuals over the 
age of 18, the discovery of treatment options is very important. Ever since the 1950s, 
a wide variety of compounds have been discovered and proven to have antagonistic 
properties for such disorders. For the last three decades, however, researchers have 
focused on a specific peptide that was discovered in 1981 by Dr. Wylie Vale and his 
colleagues at the Salk Institute in San Diego, California, corticotropin releasing factor 
(CRF). 
CRF is a 41 amino acid peptide that has been shown to play a very important 
role in an organism’s endocrine response to stress through the activation of the 
hypothalamic-pituitary-adrenal (HPA) axis. Ever since its discovery, the 
identification and characterization of the CRF receptors and family members have 
allowed for the development of novel peptide and non-peptide antagonists. 
Unfortunately, these compounds have been unsuccessful in the progression to later 
stage clinical trials that could lead to promising therapeutics.  
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There are two receptor subtypes for this family of peptides known as CRFR1 
and CRFR2. While there have been many compounds identified that can block 
CRFR1, currently, there are no known selective non-peptide antagonists for the 
CRFR2 subtype. As the two receptor subtypes share 70% sequence identity, close 
observation of the functional properties of antagonist ligands for CRFR1 may lead to 
the development of such ligands for CRFR2.  
Methods: In our current study, we focused on two residues in transmembrane 
domains (TMD) 3 (His199) and 5 (Met276) of CRFR1 that have proven to be 
important for the function of the highly selective small molecule antagonist 
antalarmin. In order to further prove the importance of these sites, we have mutated 
the two corresponding amino acids in CRFR2β to those of CRFR1: V215H in TMD 3 
and V292M in TMD 5. In addition, we mutated a third amino acid residue, M293I, in 
order to avoid the positioning of two adjacent methionine amino acids. With this 
mutant construct, CRE-luciferase and cyclic AMP radioimmunoassay methodologies 
were used to observe the function of antalarmin on CRFR1, the mutant and wild type 
CRFR2β. The accumulation of cAMP was measured intracellularly following 
stimulation by the CRF receptor peptide agonists sauvagine, isolated from frog, and 
urocortin 1, isolated from rat. 
Results: For the initial CRE-luciferase functional assay, we used the CRF receptor 
agonist sauvagine on our mutant CRFR2β to indirectly measure the accumulation of 
intracellular cAMP through the enzyme luciferase. In the presence or absence of the 
antagonist antalarmin, there were no significant changes on the function of the mutant 
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CRFR2β. On the other hand, when directly measuring the accumulation of 
intracellular cAMP via radioimmunoassay, antalarmin successfully showed a 
functional inhibitory effect on the mutant CRFR2β receptor. As expected, Ucn1 
stimulation of CRFR1 in the presence of antalarmin indicated a decrease in the EC50 
for the peptide agonist, and thus an inhibitory effect by antalarmin. Compared to 
CRFR1, we observed a similar effect for Ucn1 stimulation of the mutant CRFR2β 
receptor in the presence of antalarmin. While the presence or absence of antalarmin 
did not have a significant inhibitory effect on the wild type CRFR2β, it can be 
concluded that the mutant CRFR2β receptor possessed similar properties to the 
CRFR1 receptor with respect to antalarmin antagonist activity. 
Conclusion: In our study, we were able to further support the importance of the two 
amino acid residues in TMD 3 and 5 of CRFR1 for the function of small molecule 
antagonists. In addition, we were able to show that antalarmin, a small molecule 
antagonist known to be highly selective for CRFR1, can have a functional inhibitory 
effect on the mutant CRFR2β. The progressive study of these discrete differences 
between the two CRF receptor subtypes may enable the discovery of novel selective 
non-peptide CRFR2β receptor antagonists. 
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INTRODUCTION 
For many years, the discovery of treatments for stress and anxiety disorders has 
been a major focus in scientific research. In the United States, anxiety disorders affect 
approximately 40 million adults age 18 and older, accounting for 18% of the US 
population[1]. It has been observed in several studies that early-life stressful events, 
including physical or sexual abuse and loss of a parent, can lead to the onset of adult 
illnesses such as depression and other severe psychological problems[2, 3]. 
The search for treatment options has led to the discovery of a variety of 
compounds that have proven successful in the management of such disorders. Initial 
studies for antidepressant drug therapies date back more than half a century. In the late 
1950’s, two classes of compounds were discovered: the tricyclic antidepressants (TCAs) 
and the monoamine oxidase inhibitors (MAOIs)[4, 5]. These drugs, although in separate 
classes, share a common mechanism on the monoaminergic systems. The monoamines 
include dopamine, serotonin and noradrenaline (norepinephrine), on all of which TCAs 
and MAOIs have varying degrees of action.  
Both TCAs and MAOIs effectively increase the physiological function of 
monoamine neurotransmitters, including dopamine and serotonin, in the brain. 
Considered the standard of antidepressant pharmacotherapy, TCAs and MAOIs were 
replaced around the 1980s by the “second-generation” antidepressants known as 
selective-serotonin re-uptake inhibitors (SSRIs)[6]. Today, the main target for the 
development of therapeutic options for mood disorders is heavily focused on the activity 
of the hypothalamic-pituitary-adrenal (HPA) axis.  
 2 
Discovery of CRF and its Role on the Hypothalamic-Pituitary-Adrenal Axis 
Corticotropin releasing factor (CRF) is a 41 amino-acid peptide isolated and 
characterized from ovine hypothalamus 30 years ago by Dr. Wylie Vale and his 
colleagues at the Salk Institute[7]. Since its discovery, several groups have developed 
antibodies against CRF to further study its localization via immunohistochemical and 
radioimmunoassay techniques. The cell bodies of CRF neurons have been found 
heterogeneously distributed throughout the central nervous system (CNS), with the 
majority located within the parvocellular region of the paraventricular nucleus (PVN) of 
the hypothalamus. While the projections of the CRF neurons extend to other 
hypothalamic nuclei, as well as extrahypothalamic areas of the brain, they mainly 
converge at the median eminence, located between the pituitary gland and the 
hypothalamus, where CRF is released in a paracrine manner.  
The widespread distribution of CRF neurons has led researchers to understand the 
extent to which the peptide can serve not only as a hormone, but also as a 
neurotransmitter in the CNS. It has been well established that CRF is involved in 
endocrine, autonomic and behavioral responses to stress. For example, the release of CRF 
can exert a variety of negative effects on the cardiovascular, gastrointestinal, immune and 
reproductive systems[8]. There has been an overwhelming development of data supporting 
the critical role CRF plays in the onset of stress and anxiety disorders through the HPA 
axis. 
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Endogenous Function of CRF 
 
CRF plays an integral role in the activation of the HPA axis, and therefore, the 
control of the endocrine response to stress. Changes in internal homeostasis, or physical 
and behavioral stressors, induce neurochemical pathways to relay information to the 
CNS. Some of these pathways ultimately terminate at PVN-CRF neurons in the 
hypothalamus. To support this, studies have utilized stressors such as insulin-induced 
hypoglycemia and administration of various drugs, including morphine and naloxone, in 
rats. While hypoglycemia represents a change in internal homeostasis, morphine has been 
known to induce activity of the pituitary adrenal axis and increase adrenocorticotropin 
hormone (ACTH) response to stress. Resulting data have shown increases in CRF gene 
expression in the PVN, as well as increased CRF release from neuronal storage within the 
median eminence[9-11].  
Communication between the pituitary and the hypothalamus is carried out through 
the hypophyseal portal system. Upon PVN stimulation, CRF is secreted into the primary 
capillary plexus of the superior hypophyseal artery, located near the median eminence, 
and exits from a secondary capillary plexus within the adenohypohysis (anterior 
pituitary). Here, endocrine target cells specific for CRF known as corticotrophs are 
induced to synthesize and release ACTH via cyclic adenosine monophosphate (cAMP) 
enzyme cascades. Once the trophic hormone ACTH reaches its target tissue, the adrenal 
cortex, it induces the synthesis and release of a number of adrenal steroids including the 
glucocorticoid, cortisol (Figure 1). Specifically, the adrenal cortex is divided into three 
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tissue layers: zona glomerulosa (outer), zona fasciculata (middle), and zona reticularis 
(inner). The middle layer, zona fasciculata, is responsible for cortisol production. 
Figure 1. Hypothalamic-Pituitary-Adrenal (HPA) Axis. Stimulation from various 
stressors or changes in internal homeostasis, followed by activation of CRF neurons in 
the PVN, lead to the release of CRF, acting on the anterior pituitary corticotrophs via 
CRFR1. ACTH is then released through cAMP enzyme cascades, inducing cells of the 
zona fasciculata in the adrenal gland to release the glucocorticoid, cortisol. For further 
regulation of the HPA axis, cortisol is involved in two negative feedback loops at the 
level of the hypothalamus and the anterior pituitary via glucocorticoid receptors that 
decrease both CRF and ACTH respectively.   
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CRF mediation of the HPA axis has been repeatedly established throughout 
various studies. For example, in 1985, Westlund et al. found increased corticotrope cell 
area, accompanied by increased plasma levels of ACTH, after CRF infusions in rats. As a 
follow-up, Westlund et al. observed greater increases in corticotrope cell area and ACTH 
levels in adrenalectomized rats, most likely due to the lack of cortisol feedback[12]. In a 
similar study, McNicol et al. in 1988 demonstrated the morphological changes within the 
anterior pituitary following bilateral adrenalectomy in rats. They observed hypertrophy 
and corticotrope hyperplasia after administration of various CRF doses, suggesting that 
the mitogenic effect is driven by increased CRF concentrations[13].  
 
Feedback Control of CRF 
As with any living organism, maintenance of a level of dynamic equilibrium, also 
known as homeostasis, is vital for survival. At the onset of any physical or physiological 
event that results in a deviation from this equilibrium, several systems become activated 
that bring about various physiological and behavioral responses. While the major mode 
of action during a response to stress is the activation of the HPA axis, feedback systems 
via glucocorticoids work accordingly to bring the axis back to baseline levels.  
Among other factors that regulate the synthesis and release of CRF, cortisol is 
involved in two negative feedback loops (Figure 1). The expression of glucocorticoid 
receptors (GR) at both the hypothalamic and pituitary level has been well established. In 
1987, Liposits et al. reported the localization of glucocorticoid receptors in the 
hypothalamic PVN via ultrastructural immunocytochemical labeling[14]. In 
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adrenalectomized rats, GR-immunoreactive sites disappeared within the PVN. However, 
after cortisol administration, these sites became concentrated, suggesting cortisol’s vital 
role in regulating the expression of GR-receptors for feedback inhibition. At the anterior 
pituitary level, studies have shown the reduction of ACTH release by glucocorticoids. 
While one study described glucocorticoid’s attenuation of cAMP generation prior to CRF 
stimulation[15, 16], a separate study suggested glucocorticoid’s effect to be after cAMP 
generation[17]. With multiple sites of action, cortisol becomes a vital component in the 
constant regulation of the HPA axis. 
Interestingly, the role glucocorticoid receptors play in the regulation of the HPA 
axis has been shown to be conditional. In 1993, Plotsky et al. observed the difference in 
response to glucocorticoid feedback as a result of physical stressors versus emotional 
stressors. While susceptibility to glucocorticoid negative feedback was seen in rats under 
emotional stress (purely cognitive), rats with induced haemorrhage in the CNS displayed 
some resistance to feedback[18]. It was then implied that with the continuation of HPA 
activity under physical stress, it might be beneficial to the organism for survival. 
Compared to emotional stressors, where the organism can adapt to repeated exposure, the 
continuation of HPA activity becomes unnecessary.  
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CRF Receptor Discovery and Characterization 
 Following the discovery of CRF, two seven-transmembrane receptor subtypes 
have been identified and extensively studied: termed CRFR1 and CRFR2. CRFR1 and 
CRFR2 are classified under the class B subtype of secretin G-protein coupled receptors 
(GPCRs)[19, 20]. While both receptors share approximately 70% of their amino acid 
sequence, they are encoded by distinct genes, with major differences seen within the 
extracellular N-terminus. When a ligand binds the receptor, the G-protein becomes 
activated, generating a signal to the enzyme, adenylate cyclase, which converts adenosine 
triphosphate (ATP) into cyclic AMP. The second messenger cAMP then induces an 
enzyme cascade, activating kinases including protein kinase A (PKA). Kinases are 
responsible for downstream phosphorylation to ultimately induce genetic transcription[19]. 
While this is the major process of activation, CRF receptors do not exclusively function 
through adenylate cyclase signaling pathways[21].  
 CRF receptor expression has been observed in a wide variety of tissues, both 
central and peripheral. For example, CRFR1 is predominately found in the CNS, 
including the cerebral cortex, cerebellum, amygdala and the pituitary[22]. CRFR2 is also 
found centrally, in the lateral septum and hypothalamus, however, it is mostly expressed 
in peripheral tissue, such as cardiac myocytes, lung, skeletal muscle and vasculature[23, 
24]
.  
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The family of Class B GPCRs has been shown to exhibit a diverse splicing 
pattern, leading to multiple mRNA variants and thus, multiple isoforms of each receptor. 
While several isoforms have been discovered for CRFR1, the only fully functional form 
that is predominately expressed is CRFR1α[25]. As CRFR1 receptors are expressed in 
various tissues, the phenotypic outcome depends upon the anatomical location. The 
CRFR1 receptors located on the corticotropes of the anterior pituitary are responsible for 
mediating the production of ACTH, leading to somatic nervous system activation and 
regulation of the response to stress[25]. Studies have shown that mice devoid of the 
CRFR1 receptor display anxiolytic-like behavior and impaired response to stress[26, 27].  
Three isoforms (α, β and γ) of CRFR2 have been identified and characterized in 
human[28]. Even though CRFR2 isoforms are located in various tissues, no differences in 
function have been found[28]. Interestingly, studies have observed a counteracting role for 
CRFR2 involvement in the HPA axis. In 2000, Bale et al. generated CRFR2 deficient 
mice, and observed increased anxiety-like behavior and increased activity of the HPA 
axis[29]. Such results suggest that the endogenous function of CRFR2 is to dampen or aid 
in the modulation of the endocrine response to stress induced by CRFR1.  
To further support the suggestion that CRFR1 and CRFR2 play opposing roles in 
the regulation of an organism’s response to stress, studies have developed mice models 
deficient in both receptors. These studies found a significant decrease in HPA axis 
activity, along with lower circulating levels of ACTH[30, 31]. Although the two receptor 
subtypes share the majority of their amino acid sequence, their distribution throughout 
the body allows for diverse physiological functions.  
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Peptide Agonists for CRF Receptors 
Ever since the characterization of CRF, there has been the discovery of a growing 
number of mammalian and non-mammalian ligands within the CRF peptide family. Two 
non-mammalian peptides that have high homology with CRF are Urotensin (Uro) and 
Sauvagine (Svg), isolated from fish and amphibian respectively[32, 33]. Both Uro and Svg 
have been shown to increase cAMP in CRFR2 transfected cells with a higher efficacy 
compared to CRF, suggesting these peptides are the preferred ligand[23, 34, 35]. To further 
support this implication, the distribution of urotensin-like immunoreactivity is similar to 
the expression patterns of CRFR2, but not CRFR1, within the Edinger-Westphal 
nucleus[36].  
Recently, a new mammalian peptide within the CRF family has been discovered 
in the rat brain, known as urocortin 1 (Ucn 1) (Table 1). Urocortin 1 shares 63% sequence 
identity with Uro, and 45% sequence identity with CRF[36]. Urocortin 1 has been shown 
to induce the accumulation of cAMP, followed by the stimulation of ACTH synthesis and 
release. However, the binding and functional efficacy of Ucn 1 is higher than that of CRF 
on both CRFR1 and CRFR2β. More specifically, it has been established that Ucn 1 binds 
to CRFR2β 40 times more strongly compared to CRF, while only six times more strongly 
to CRFR1[36]. 
Since the discovery of Ucn1, two additional members of this peptide family have 
been identified and characterized (Table 1). The second member of the urocortins, termed 
urocortin 2 (Ucn 2) shares 58% amino acid identity with CRF and 55% amino acid 
identity with Ucn 1[37]. Even though Ucn 2 is a CRF-related neuropeptide, its distinction 
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lies in its highly selective binding by CRFR2. The affinity of Ucn 2 on both CRF receptor 
subtypes was determined via radioreceptor assays. Upon evaluation, there was a 
significant decrease in the binding of Ucn 2 to CRFR1 when in competition with 
radiolabeled sauvagine, however, equal potency when bound to CRFR2 when compared 
to Ucn 1. Interestingly, unlike the immunoreactive distribution of Ucn 1, the expression 
pattern of the early gene product Fos by Ucn 2 stimulation does not follow the 
distribution of CRFR2[37]. 
Finally, the most recent of the urocortins, known as urocortin 3 (Ucn 3), shares 
40% identity with Ucn 2. In addition, Ucn 3 has been shown to be more distinct from 
Ucn 1 and CRF, as there is only 18% and 26% identity in amino acid sequence, 
respectively[38]. Similar to Ucn 2, Ucn 3 binds with high selectivity by CRFR2, and is 
much less potent than Ucn 1 when binding to CRFR1. Based on mRNA expression, 
receptor binding and cellular activation studies, it has been implied that the CRF-related 
urocortins are the native ligands for CRFR2. With its vast distribution in the periphery, 
the activation of CRFR2 by Ucn1-3 may serve an alternative role compared to CRF in the 
response to any stress stimuli.  
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Table 1. Various amino acid sequences for CRF Family Ligands. Binding constants 
of each peptide (Ki) in nanomolar concentrations are listed for both CRF receptor 
subtypes. References for each peptide sequence are as follows: CRF[39], Sauvagine[40], 
Urocortin 1[39], Urocortin 2[38] and Urocortin 3[38]. 
 
The discovery of these agonists has furthered the scientific study of the 
importance of CRF, and its family members, in regulating the endocrine stress response. 
Several studies have generated mice that either over express or are deficient in CRF 
peptides and receptors. For example, while CRF deficient mice show attenuated or absent 
HPA axis activity, resulting in reduced ACTH levels, Ucn 1-knockout mice had normal 
stress-simulated levels of HPA axis activity and ACTH.[41-44] This suggests that while 
CRF receptors have a high affinity for Ucn 1, it may not play as important of a role in the 
stress response as CRF.  
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CRF Peptide Antagonist Studies 
 As the search for therapeutic options to manipulate the CRF system continues, 
there have been several studies that have developed and characterized a myriad of CRF 
receptor antagonists. In studies other than those involving CRF, the generation of peptide 
antagonists has resulted from the substitution or deletion of specific amino acids from the 
known native peptide sequence. This strategy has been previously used, for example, 
with the progression of gonadotropin-releasing hormone (GnRH) antagonist development 
established from the deletion of one amino acid at a time. This led researchers to establish 
the importance of specific amino acids in the agonist peptide in order to develop novel 
peptides with antagonist properties[45]. 
In 1984, Rivier et al. synthesized and characterized the antagonist potential of 
polypeptide CRF analogs with α-helical structures. The results of in vitro studies showed 
the increased potency of the analog α-helical CRF(9-41), successfully inhibiting release of 
ACTH[46]. In additional studies, Fisher et al. in 1991 performed in vivo assays to compare 
the effects of α-helical CRF(9-41) to CRF. It was observed that an antagonist:agonist ratio 
between 6:1 – 12:1 was required for α-helical CRF(9-41) to exhibit an inhibitory effect. In 
addition, hypotension and tachycardia were prevented with an antagonist:agonist ratio of 
6:1, whereas a ratio of 3000:1 was required to completely inhibit the rise of plasma 
ACTH levels[47]. The varying efficacy of α-helical CRF(9-41) to serve as a CRF antagonist 
provides further support to the notion of the vast biological effects of CRF and its 
receptors.  
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Another peptide antagonist that was developed and has a high affinity for the CRF 
receptors is astressin[48]. The increased potency and binding affinity of astressin by 
CRFR1 and CRFR2β, compared to that of CRF, was a result of the introduction of a 
structural component known as a lactam bridge[48]. Further support included the 
significantly reduced ACTH release in both stressed adrenal-intact and non-stressed 
adrenalectomized rats. The implication that structural differences in these peptides 
account for various inhibitory efficacies has led to the discovery of multiple antagonists, 
each with distinct potencies and binding affinities to CRF receptor subtypes.  
It is important to mention that although CRF peptide antagonists have proven to 
be effective in the inhibition of endogenous effects, such peptides are incapable of 
crossing the blood-brain-barrier. Therefore, they are unable to access essential CRF 
neurons in the CNS. As previously mentioned, although these central neurons provide the 
initial signal for the activation of the HPA axis, those located in extrahypothalamic 
regions also play a vital role in the onset of depression and anxiety disorders.  
Over the years, there have been several CRF non-peptide receptor antagonist 
compounds that have been developed with the ability to enter the brain. These non-
peptidic small molecules probably bind to the transmembrane domain of the receptor, 
altering the conformation of the protein, thus preventing agonist ligand binding and 
activation. Small molecule antagonists that bind to CRFR1 may share common molecular 
features, known as a pharmacophore, indicating similar binding sites on the receptor. 
However, since the discrete structures vary between each compound, the resulting 
conformational change will never be the same. Thus, studies have observed marked 
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differences in receptor pharmacology. The pharmacophore of small molecule antagonists, 
in turn, allows for the progressive identification of novel ligands that will induce a similar 
biological response.  
 Unfortunately, while some of these non-peptidic small molecules (Figure 2) have 
been able to reach phase two clinical trials, they have not yet been proven to have 
therapeutic value. For example, the first CRFR1 antagonist to enter into clinical trials was 
NBI 30775, or R121919. The water-soluble pyrrolopyrimidine was tested on 24 patients 
with depressive symptoms at the Max Planck Institute of Psychiatry in Munich Germany, 
where it was well absorbed when given orally, and bound to central CRFR1 with high 
affinity. However, even though this compound generated initial positive results, R121919 
was subsequently discontinued due to liver toxicity[49, 50].  
Additional clinical trials for generalized anxiety disorder (GAD), social anxiety 
disorder (SAD), major depressive disorder (MDD), irritable bowel syndrome (IBS) and 
post-traumatic stress disorder (PTSD) with compounds including GW-876008 
(GlaxoSmithKline), CP316.311 (Pfizer)[51], SSR125543 (Sanofi), ONO-2333Ms (Ono 
Pharmaceutical), and BMS-562086 (Bristol Myers Squibb) (Figure 2) have also 
unfortunately produced negative results[50]. Currently, the small molecule NBI 77860 
(GSK561679) is being tested in a phase two clinical trial for PTSD[52].   
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Figure 2. Structures of small molecule antagonists. Each compound listed has reached 
phase 1 or 2 clinical trials for potential therapeutic options for various psychiatric 
disorders. Unfortunately, all clinical trials with these compounds have failed. 
Note: Published clinical trial studies can be found at clinicaltrials.gov (NCT reference 
number listed above). References for structures that do not have an NCT number, or 
those that have not been previously referenced include NBI-34041[53] and CRA-5626 / 
R317573[54]. 
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To date, there are no known non-peptide antagonists for CRFR2. With the 
increasing amount of data supporting the role of CRFR2 in the response to stress, it is 
important to develop such compounds. As the two CRF receptor subtypes share the 
majority of their amino acid sequence, the close observation of CRFR1 receptor 
antagonist function may lead to the development of antagonist ligands for CRFR2. In 
1997, Liaw et al. discovered the importance of two amino acids in transmembrane 
domains (TMD) 3 (His199) and 5 (Met276) of CRFR1, for the binding of the CRF 
antagonist NBI 27914. Evidence for the selectivity of this compound has been shown by 
the fact that the binding affinity of NBI 27914 decreased when these two amino acids 
were mutated to those corresponding in CRFR2[55].  
Webster et al. characterized the antagonistic effects of the pyrrolopyrimidine 
compound antalarmin in 1996 (Figure 3). Both in vitro and in vivo studies confirmed the 
inhibition of CRF-induced ACTH release by antalarmin with the observed displacement 
of CRF binding to CRFR1[56]. Follow up studies performed by Deak et al. in 1999 
reported that the non-peptidic small molecule successfully blunted stress-induced 
behavioral changes regulated by central CRFR1, demonstrating its ability to cross the 
blood-brain-barrier.  
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Figure 3. Structure of the small molecule antagonist antalarmin. Discovered in 1996, 
antalarmin has never been administered in human, but has been observed to successfully 
inhibit the actions of CRF in the release of ACTH during stress stimuli in rat and 
monkey[56].  
 
In our present study, we used the prototypic high affinity antagonist antalarmin, 
which has also been shown to be highly selective for CRFR1[56]. In order to further 
understand the functional properties of CRFR2 receptors to antagonist ligands, we 
mutated the two amino acids in TMD 3 and 5 of CRFR2β that correspond to His199 and 
Met276 of CRFR1 (Figure 4). In addition, to avoid the positioning of two adjacent 
methionine amino acids, we introduced the third mutation, M293I. As stated above, since 
each small molecule results in unique conformational changes to the receptor protein, 
elucidating the functional importance of such amino acids can lead to the development of 
novel small molecule antagonists that will be specific for CRFR2.  
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Figure 4. Partial relevant amino acid sequence for CRFR2β (top sequence per line) 
and CRFR1 (bottom sequence per line) from rodent. Residues highlighted in red 
indicate those that are identical to each receptor. The three residues that are boxed and in 
blue indicate the sites of mutation in our present study. 
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To observe the functional effects of antalarmin, we initially performed a CRE-
luciferase assay on the mutant CRFR2β. The CRE-luciferase reporter gene is transfected 
and expressed in cells, and integrates into the CREB pathway. CREB (cAMP response 
element-binding protein) is a transcription factor, which when bound to DNA sequences 
known as cAMP response elements (CRE), initiates the transcription of downstream 
genes. Upon receptor stimulation, adenylate cyclase is activated, converting ATP to 
cAMP. The cAMP enzyme cascade then progresses to activate PKA, which ultimately 
activates CREB. Once CREB binds the expressed CRE-luciferase gene, the enzyme 
luciferase is produced. Activation of luciferase via the substrate luciferin emits light, 
allowing the indirect quantification of intracellular cAMP, which can be measured by a 
Modulus Microplate Luminometer. Thus, quantifying the amount of light emitted by 
luciferase can provide an indication of the relative amount of cAMP produced due to 
receptor activation.   
 In addition to the CRE-luciferase assay, which is an indirect measure, we also 
performed direct measures of the amount of intracellular cAMP produced by the 
stimulation of the three receptors via cAMP radioimmunoassay (RIA).  
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METHODS 
 
Construction of the CRFR2β Mutant 
 
To construct a CRFR2β receptor similar to the CRFR1 isoform, myc-tagged 
CRFR2β DNA was subcloned into the ampicillin resistant expression vector 
pcDNA3.1(+) using restriction enzymes EcoR1 and XhoI via PCR-methodology. The 
myc-tag is a polypeptide sequence added to DNA for assays that utilize antibody 
recognition. In our case, the use of myc-tagged CRFR2β DNA would allow us to ensure 
the expression of the receptors on the surface of the cells. With this DNA template, 
multiple site-directed mutagenesis was performed using the QuickChange Lightning Site-
Directed Mutagenesis Kit (Agilent Technologies Santa Clara, CA, USA). The three 
mutated sites, located within transmembrane domains 3 and 5 of the receptor, are V215H 
(TMD3), V292M (TMD5), and M293I (TMD5). The generated plasmid was then 
transformed into XL10-Gold Ultracompetent Cells, where transformation efficiency was 
increased using β-mercaptoethanol. After transformation, 50µl and 200µl aliquots were 
plated on carbenicillin agar plates. Colonies that grew were indicative of successful 
subcloning of the receptor DNA into the pcDNA3.1(+) vector.  
 
Plasmid Preparation 
To extract and purify the mutant DNA for future transfection, plasmid preparation 
methodology was used via Invitrogen PureLink HiPure Plasmid Maxiprep Kit (Life 
Technologies Grand Island, NY, USA). Colonies from the carbenicillin agar plates were 
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selected and grown overnight in culture flasks containing 150ml circle grow media, 
including 150µl carbenicillin. Our goal was to obtain a high DNA yield of at least 1µg/µl. 
 
Transfection into COSM6 Mammalian Cells for CRE-Luciferase Assay 
 For the expression of the mutant CRFR2β, we transfected the plasmid DNA, in 
the pcDNA3.1(+) vector, into COSM6 mammalian cells. These cells are a derivative of 
the COSM7 kidney fibroblast cell line from the African green monkey[57, 58]. Prior to 
transfection, 2.5µg of CRFR2β plasmid DNA was added to 750µl of Opti-MEM media 
(Gibco, Life Technologies Grand Island, NY, USA), in addition to 2.5µg of CRE-
luciferase and 2.5µg of β-Galactosidase (βGAL) plasmids. We also prepared a separate 
mixture of 30µl of Lipofectamine 2000 (Invitrogen, Life Technologies Grand Island, NY, 
USA) in 750µl of Opti-MEM media. Lipofectamine is a cationic liposome complex 
containing lipid subunits. This formulation can entrap transfection material such as DNA 
plasmid, and cross the negatively charged plasma membrane of cells, providing a means 
for DNA to enter into the cytoplasm for further replication or transcription. The 750µl of 
the plasmid DNA mixture was then added to the 750µl of the Lipofectamine 2000 
mixture, for a total of 1.5ml. This mixture was allowed to incubate at room temperature 
for 20 minutes, and then we slowly added 500µl to approximately 2.5 million COSM6 
cells in two 10cm tissue culture dishes. The transfection was allowed to incubate 
overnight at 37 degrees Celsius.  
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CRE-Luciferase Assay for Functional Study 
 In order to test whether the small molecule antagonist, antalarmin, functionally 
inhibits chemical signaling through the CRF receptors, we initially decided to perform a 
CRE-Luciferase assay with the mutant CRFR2β and serial dilutions of the CRF receptor 
agonist, sauvagine. As described above, plasmid DNA was transfected into COSM6 cells. 
After the overnight incubation, the cells were removed from the culture dish with trypsin, 
a proteolytic enzyme, followed by the distribution of 300µl of the cells to a 48 well plate: 
experiments were performed in triplicate wells. To ensure the cells would adhere to the 
bottom of the plate for the duration of the assay, 300µl of polylysine was added to each 
well, and incubated at room temperature for one hour. Polylysine is commonly used in 
tissue culture to improve the adherence of cells because of its charge.  
After this incubation period, the plate was washed three times with HEPES 
dissociation buffer (HDB). Prior to the addition of the serial dilutions of sauvagine, 10µl 
of 10µM antalarmin was added to each well and allowed to incubate for one hour at 37 
degrees Celsius. The various sauvagine concentrations added are as follows: 0.03nM, 
0.01nM, 0.1nM and 1nM. After the addition of the peptide dilutions, the plate was left to 
incubate for 3 hours at 37 degrees Celsius.  
For this experiment, it was important to normalize the enzyme expression levels. 
For this normalization, we initially performed a βGAL assay. Following the four-hour 
treatment period, the entire plate was washed once with HDB. Then, 150µl of 1% Triton 
lysis buffer with 1mM DTT was added to each well. The lysis buffer contains 25mM 
glycylglycine at a pH of 7.8, 15mM MgSO4, 4mM EGTA and 1% Triton X-100. The 
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plate was then placed on ice for 15 minutes to lyse the cells. To continue with the assay, 
20µl of each sample was transferred to a 96 well plate containing 100µl of 1.5mg/ml 
ONPG in βGAL buffer, including β-mercaptoethanol. ONPG, the substrate for βGAL, is 
initially a colorless compound. The product of βGAL catalysis of ONPG is ONP, giving 
a yellow color. Using the Modulus Microplate Luminometer, the rate of appearance of 
yellow color provides data for the amount of enzyme produced as a result of receptor 
activation and cAMP enzyme cascades.  
Following normalization, we continued to perform the CRE-luciferase assay. 
From the original sample, 20µl was added to 50µl of a Luciferin mixture in a 96 well 
plate. This mixture contained 0.3mM of Luciferin, 15mM MgSO4, 25mM glycylglycine 
(pH 7.8), 4mM EGTA, 1mM ATP, 1mM DTT and 86.1µl of water. The activation of the 
luciferase enzyme led to catalysis of luciferin, emitting light at a rate measured by the 
Modulus Microplate Luminometer. As with the βGAL assay, data obtained provided the 
relative amounts of the luciferase enzyme produced as a result of receptor activation and 
cAMP enzyme cascades. All data values were then analyzed by Prism (GraphPad, San 
Diego, California) to obtain data graphs. 
 
Transfection into COSM6 Mammalian Cells for cAMP RIA 
Expression of wild type and mutant CRF receptors was accomplished by 
transfecting myc-tagged CRF receptor plasmid DNAs, in the pcDNA3.1(+) vector, into 
COSM6 mammalian cells. Prior to transfection, 10µg of CRF receptor plasmid DNAs in 
1.5ml of Opti-MEM media was added to 30µl of Lipofectamine 2000 in 1.5ml of Opti-
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MEM, for a total of 3ml. This mixture was allowed to incubate at room temperature for 
20 minutes, and then slowly added to approximately 4 million COSM6 cells in a 10cm 
tissue culture dish. The transfection was allowed to incubate overnight at 37 degrees 
Celsius to ensure maximum expression. 
 
Cyclic AMP Radioimmunoassay’s for Functional Study  
The peptide agonist, urocortin 1 (Ucn 1), was administered in various 
concentrations to stimulate accumulation of intracellular cAMP. For these assays, the 
serial dilutions of Ucn 1 were assayed using a 48-well plate: experiments were performed 
in triplicate wells. The peptide concentrations used for both CRFR1 and the mutant 
CRFR2β, as these receptors are assumed to be the same, were as follows: 0.01nM, 
0.03nM, 0.1nM, 0.3nM, 1nM, and 3nM. The peptide concentrations used for CRFR2β 
were as follows: 0.001nM, 0.01nM, 0.03nM, 0.1nM, 0.3nM, and 1nM. Since Ucn 1 is 
known to be more potent on CRFR2 compared to CRFR1, the lowest concentration for 
the wild type CRFR2β was reduced 10 fold.  
Initially, a pilot RIA was run for each receptor. Plasmid DNA was transfected into 
COSM6 cells as described above. After the overnight incubation, the transfected cells 
were removed from the culture dish with trypsin and added to a 48 well plate previously 
treated with polylysine. Approximately 50k of the transfected cells were then added to 
each well, and allowed to incubate overnight at 37 degrees Celsius.  
As stated above, the CRF receptor agonist Ucn 1 was used to stimulate the 
intracellular production of cAMP. Prior to addition of the peptide, each well was washed 
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twice with HDB, and once with an assay buffer (DMEM, 0.1% BSA). After the third 
wash, 300µl of the assay buffer was added to each well, and allowed to incubate for two 
hours at room temperature. In order to ensure that the maximum amount of produced 
cAMP was measured throughout the RIA, 20µl of a phosphodiesterase inhibitor, IBMX, 
was added to each well. The enzyme, phosphodiesterase, is responsible for cleaving the 
phosphodiester bond in cAMP to regulate its function via degradation.  
After 20 minutes of incubation with IBMX solution (diluted in assay buffer), the 
various concentrations of Ucn 1 were added to each respective well. Stimulation was 
allowed to occur for 20 minutes at 37 degrees Celsius, and the reaction was stopped by 
aspirating the media and adding 300µl of 95% ethanol/0.1N HCl. The entire plate was 
placed on dry ice for 30 minutes in order to lyse the cells, thus obtaining the cAMP in 
solution. The 300µl from each well was transferred into separate 1.5ml Eppendorf tubes, 
and lyophilized to dryness in a vacuum centrifuge overnight.  
The cAMP RIA was performed using the cAMP [125I] RIA Kit by PerkinElmer 
Life Sciences (Waltham, MA, USA). The entire RIA was run using 12mm x 75mm glass 
tubes. A standard curve was initially set up using the cAMP standard provided in the kit. 
For the lyophilized samples, each tube was re-suspended in 150µl of the assay buffer 
provided in the kit. Then, 50µl of each sample was added to a separate tube, followed by 
50µl of the primary antibody and 50µl of hot cAMP tracer, both provided. The same 
amounts of antibody and tracer were also added to the standard curve tubes.  
The measurements recorded in this assay include the amount of cAMP tracer 
(125I-labeled cAMP) bound to the antibody complex as determined by a gamma counter. 
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The more counts recorded in any given sample indicate a higher ratio of the antibody 
complex bound to the tracer compared to the amounts of the given unknown sample. 
Therefore, lower counts indicate a larger amount of cold cAMP (produced from the 
stimulated transfected cells or the standard cAMP) bound to the antibody complex 
compared to the tracer.  
Once all data were collected, values were entered into the computer program, 
Prism, to establish dose-response curves. From these curves, we were able to compare 
and contrast results for the efficacy of Ucn 1 on the three receptors tested.   
After successful data were obtained for each receptor with Ucn 1 stimulation, our 
next step was to test the function of the small molecule antagonist, antalarmin. The same 
protocol for receptor transfection was followed as described above. For receptor 
stimulation, the phosphodiesterase inhibitor IBMX was added for 15 minutes after the 
two hour incubation with buffer, followed by the addition of 20µl of antalarmin at a final 
concentration of 10µM. The same concentration was added to every well on the plate, 
and allowed to incubate for 30 minutes before addition of Ucn 1. This pre-incubation 
period with antalarmin was to ensure maximal binding of the antagonist to the expressed 
receptors.  
The plate was organized such that half of the wells would be treated with 
antalarmin, while the other half were control, treated with buffer and DMSO, since 
antalarmin was initially prepared in DMSO. After the 30 minute period, the same 
concentrations of Ucn 1 used in the previous pilot assays were used for stimulation. 
Concentrations of cAMP were then measured via PerkinElmer cAMP RIA as before, and 
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data were analyzed by Prism. With the concentration curves produced, we were able to 
compare and contrast how antalarmin functions across the two CRF receptor subtypes.  
 
RESULTS 
 
Construction of the CRFR2β Mutant 
 
 Using the QuickChange Lightning Site-Directed Mutagenesis Kit, we 
successfully constructed a CRFR2β mutant. The DNA sequence was confirmed by 
GenBank sequencing. With the three point mutations, V215H, V292M and M293I, the 
CRFR2β mutant mimicked CRFR1 regarding the amino acid sequence. Using the 
CRFR1, CRFR2β wild type and CRFR2β mutant receptors, we tested the hypothesis that 
the mutated sites in transmembrane domains 3 and 5 are vital for the function of the small 
molecule antagonist, antalarmin.  
 
CRE-Luciferase Assay 
 In theory, the addition of the antagonist antalarmin prior to sauvagine stimulation 
should block the function of the receptor, and decrease the relative amounts of 
intracellular luciferase, and thus intracellular cAMP, stimulated by sauvagine. However, 
the stimulation of cAMP by sauvagine in the presence or absence of antalarmin was 
indistinguishable up to the concentrations we tested (Figure 5). Since the CRE-luciferase 
assay did not clearly demonstrate antagonism of sauvagine stimulation by antalarmin, we 
directly examined intracellular cAMP levels using a cAMP radioimmunoassay.  
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Figure 5. CRE-luciferase functional assay for myc-CRFR2β. Sauvagine stimulation at 
various concentrations in the presence or absence of antalarmin did not show any 
significant change in the relative amount of the luciferase produced, and therefore, the 
relative amount of intracellular cAMP.   
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Cyclic AMP 
   Ucn 1 Stimulation of Intracellular Accumulation of cAMP 
 The pilot studies of each receptor, using Ucn 1 for stimulation, allowed us to 
establish a relevant concentration range. The data point on the lowest part of each curve 
represents the cells in the assay that were not treated with Ucn 1, providing the basal, or 
normal, level of cAMP found within the cell. As expected, the calculated EC50 values 
shown in Figure 6 and Figure 7 are almost identical, suggesting equivalent potencies of 
Ucn1 stimulation. In addition, when including the 95% confidence intervals for the EC50 
values, there is a considerable amount of overlap. Since the expression levels of the 
receptors were not identical between each assay, there was a difference in the absolute 
scale for average cAMP concentration.  
The EC50 value for Ucn 1 stimulation on the wild type CRFR2β (Figure 8) was 
lower compared to the EC50 value for Ucn 1 stimulation on both CRFR1 and the mutant 
CRFR2β (Figure 5 and Figure 6). As a result, the overall curve was shifted to the left, 
indicating the higher affinity of Ucn 1 for the wild type CRFR2β. These initial pilot 
assays provided useful data for the investigation of antalarmin function across the three 
receptors via cAMP RIA’s. 
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Figure 6. Ucn 1 stimulation of cAMP in myc-CRFR1-expressing COSM6 cells. The 
curve represents the accumulation of intracellular cAMP due to Ucn 1 stimulation at 
various concentrations. The calculated EC50 value with the 95% confidence interval is 
0.8 (0.4 – 1.4)x10-10 M (Prism, GraphPad San Diego). Data represent triplicate 
determinations at each concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Ucn 1 stimulation of cAMP in mutant myc-CRFR2β-expressing COSM6 
cells. The curve represents the accumulation of intracellular cAMP due to Ucn 1 
stimulation at various concentrations. The calculated EC50 value with the 95% 
confidence interval is 0.5 (0.3 – 1.0)x10-10 M (Prism, GraphPad San Diego). Data 
represent triplicate determinations at each concentration. 
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Figure 8. Ucn 1 stimulation of cAMP in wild type myc-CRFR2β-expressing COSM6 
cells. The curve represents the accumulation of intracellular cAMP due to Ucn 1 
stimulation at various concentrations. The calculated EC50 value with the 95% 
confidence interval is 0.2 (0.06 – 0.4)x10-10 M (Prism, GraphPad San Diego). Data 
represent triplicate determinations at each concentration. 
 
Ucn 1 Stimulation of Accumulation of Intracellular cAMP in the Presence of 
Antalarmin  
 
With a well-established range of Ucn1 concentrations, the effects of antalarmin on 
Ucn 1 stimulation were evaluated. In theory, antalarmin should bind to the receptors 
CRFR1 and the mutant CRFR2β with a higher affinity compared to the wild type 
CRFR2β, therefore inhibiting Ucn 1 function on the former receptors. For both CRFR1 
and the mutant CRFR2β, there was an overall shift to the right for the curve that 
represents cells treated with antalarmin (Figure 9 and Figure 10). The calculated EC50 
values for Ucn 1 stimulation in the presence of antalarmin are also higher in 
concentration compared to the calculated EC50 value for Ucn 1 stimulation in the 
absence of antalarmin. With the overall shift in the curves, representing an increase in 
EC50 values, it is clear that antalarmin had an inhibitory effect on the function of Ucn 1. 
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In contrast, there was very little difference observed in the EC50 values for the 
wild type CRFR2β treated with or without antalarmin (Figure 11). Because the calculated 
EC50 values were not significantly different for CRFR2β in the presence or absence of 
antalarmin, we can suggest that there was minimal inhibitory effect on the receptor. 
Similar to the previous assay, since the expression levels of the cells were not the same, 
the scales for the average cAMP measured varied among each receptor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Ucn 1 stimulation of cAMP in myc-CRFR1-expressing COSM6 cells in the 
presence or absence of antalarmin. The blue curve indicates absence of antalarmin, 
while the red curve indicates cells treated with 10µM antalarmin. The inhibitory effect of 
antalarmin on the intracellular production of cAMP is evident by a shift to the right (red 
curve). The calculated EC50 value with the 95% confidence interval for Ucn 1 
stimulation in the presence of antalarmin is 1.1 (0.3 – 3.8)x10-9 M, whereas the calculated 
EC50 value with the 95% confidence interval for Ucn 1 stimulation in the absence of 
antalarmin is 0.4 (0.08 – 1.6)x10-9 M. Data represent triplicate determinations at each 
concentration.  
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Figure 10. Ucn 1 stimulation of cAMP in mutant myc-CRFR2β-expressing COSM6 
cells in the presence or absence of antalarmin. The blue curve indicates absence of 
antalarmin, while the red curve indicates cells treated with 10µM antalarmin. As with 
CRFR1, there is an observable inhibitory effect by antalarmin on the intracellular 
production of cAMP indicated by a shift to the right (red curve). The calculated EC50 
value with the 95% confidence interval for Ucn 1 stimulation in the presence of 
antalarmin is 0.3 (0.1 – 0.5)x10-9 M, whereas the calculated EC50 value with the 95% 
confidence interval for Ucn 1 stimulation in the absence of antalarmin is 0.01 (0.005 – 
0.03)x10-9 M. Data represent triplicate determinations at each concentration.  
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Figure 11. Ucn 1 stimulation of cAMP in myc-CRFR2β-expressing COSM6 cells in 
the presence or absence of antalarmin. The blue curve indicates absence of antalarmin, 
while the red curve indicates cells treated with 10µM antalarmin. With very little shift in 
the presence of antalarmin (red curve), this suggests that there was no significant 
inhibitory effect by antalarmin on the intracellular production of cAMP in the wild type 
receptor. The calculated EC50 value with the 95% confidence interval for Ucn 1 
stimulation in the presence of antalarmin is 0.08 (0.02 – 0.4)x10-9 M, and the calculated 
EC50 value with the 95% confidence interval for Ucn 1 stimulation in the absence of 
antalarmin is 0.01 (0.005 – 0.04)x10-9 M. Data represent triplicate determinations at each 
concentration.   
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DISCUSSION 
 Over the years, there have been a number of studies using peptide agonists and 
antagonists to better understand the roles CRF and its family members play in the 
endocrine response to stress. Ever since the discovery of CRF, a wide variety of peptide 
and non-peptide compounds have been developed as potential treatment options for 
psychiatric disorders. Unfortunately, while some these compounds have reached phase 
two clinical trials, and proven to negatively manipulate the endocrine response to stress, 
they have been unsuccessful in the progression to later stage clinical trials that could lead 
to promising therapeutics.  
 Several studies have approached this issue from various angles. Data from these 
studies have proven the importance of specific amino acid residues in the transmembrane 
domains of the CRF receptors for non-peptide antagonist ligand binding. For instance, 
Liaw et al. in 1997 observed the highly specific binding of the small molecule non-
peptide antagonist NBI 27914 to CRFR1 depends on two amino acids in transmembrane 
domains 3 (His199) and 5 (Met276). With the mutation of these two sites to the 
corresponding amino acids of CRFR2, binding affinity of the non-peptide antagonist 
decreased. As there are no antagonists for CRFR2, careful observation of the molecular 
interactions between antagonist ligands and CRFR1 may lead to the discovery of 
antagonists for CRFR2. 
 Our study took a different approach to provide insight for the differences in 
antagonist function on CRF receptors. Using the same amino acid residues as previous 
studies, we instead mutated the two key residues in the transmembrane domains of 
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CRFR2β to the corresponding residues found in CRFR1. As a result, this mutant 
CRFR2β receptor, in theory, might mimic the functional properties of the CRFR1 
receptor with respect to small non-peptide antagonists, and thus provide a basis for the 
discovery of selective molecules targeting CRFR2. As our investigation consisted of 
functional assays, in order to confirm the expression of the receptors on the cell surface, 
we utilized myc-tagged DNA sequences for each receptor. Should any assay require 
troubleshooting, we could directly examine whether the receptors were appropriately 
expressed on the cell surface via antibody recognition assays. To further prove the 
importance of the two sites in transmembrane domains 3 and 5, we used the small 
molecule antagonist antalarmin and peptide agonists sauvagine and Ucn 1 to study 
differences in receptor function.  
 The first functional assay we used was CRE-luciferase. In this bioluminescence 
assay, we were able to indirectly measure the relative amounts of cAMP produced via 
activation of the enzyme luciferase. CRE-luciferase is the reporter gene in the final step 
of the CREB pathway. We initially transfected the mutant CRFR2β into COSM6 cells 
along with CRE-luciferase and βGAL plasmids. The importance of adding βGAL to this 
assay was to normalize the expression levels of the enzymes produced. Upon stimulation 
of the receptor by the agonist sauvagine, cAMP would be generated, followed by the 
progression of an enzyme cascade, resulting in the binding of the transcription factor 
CREB to the CRE-luciferase gene, producing the enzyme luciferase. With the 
accumulation of intracellular luciferase, we lysed the cells and added a small aliquot of 
the lysate to a solution containing the substrate luciferin. The action of luciferase on its 
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substrate luciferin emits light that was measured by a Modulus Microplate Luminometer. 
The data obtained provided us with the relative amounts of accumulated intracellular 
luciferase, and by extension, the accumulation of intracellular cAMP due to receptor 
activation.  
 In order to examine the effects of antalarmin on our mutant CRFR2β, we added 
antalarmin prior to sauvagine stimulation. In theory, antalarmin would bind to the 
receptor, creating an inhibitory effect. The data generated were all almost identical, 
whether in the presence or absence of antalarmin. While the CRE-luciferase assay is a 
cheaper and less time consuming assay, unfortunately, this assay did not yield conclusive 
data. We therefore chose to perform direct intracellular cAMP measurements using 
cAMP radioimmunoassays.  
Prior to adding antalarmin to the transfected cells for the cAMP RIA functional 
assays, we performed a pilot study for each receptor to establish a comparable 
concentration range for the peptide agonist Ucn 1. Once the concentration ranges were 
determined, we proceeded to evaluate the effects of antalarmin. Antalarmin was allowed 
to bind to transfected COSM6 cells expressing each type of receptor before stimulation 
with Ucn 1. For both the mutant CRFR2β and CRFR1, the cAMP concentration curves 
for cells treated with antalarmin were shifted to the right compared to curves obtained in 
the absence of antalarmin, indicating that the small molecule had a functional inhibitory 
effect. For the wild type CRFR2β, we did not observe any significant change in the 
function of the receptor when stimulated by Ucn 1 in the presence or absence of 
antalarmin. 
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 Due to the fact that the receptor had to be transfected into cells for each individual 
experiment, the amount of receptor expression from one assay to the other was not 
identical. This is evident from the absolute levels of stimulated cAMP observed in each 
experiment. The cAMP concentration axis for each data graph was therefore not the 
same, where higher expression levels yielded higher levels of cAMP. However, the 
overall shift to the right for antalarmin-treated cells is sufficient to indicate successful 
functional inhibition. On the other hand, the calculated EC50 values, specifically those 
for Ucn 1 stimulation of CRFR1 in the presence and absence of antalarmin, show some 
overlap when the 95% confidence intervals are taken into consideration. This could 
suggest that there was not a significant difference in receptor function in the presence of 
antalarmin. While the assays performed in this study were preliminary, as each was only 
performed once, it is important to repeat the experiments to validate the conclusions we 
have made thus far. 
For future studies, the use of stable cell lines for transfections would be useful to 
ensure a constant level of receptor expression. In addition, utilizing other CRF receptor 
peptide agonists such as CRF or sauvagine on the different receptor subtypes could 
elucidate the functional pharmacological profile of these receptors. The results provided 
from our study suggest that antalarmin, known to be highly selective for CRFR1, can 
have an inhibitory effect on CRFR2, at least to the β-subtype, with the simple 
modification of the two amino acid residues. Such data can thus lead to the discovery of 
small molecules that may possess high binding specificity, selectivity and function for 
CRFR2 receptors.  
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CONCLUSION 
Stress and anxiety disorders take a heavy toll on the American population, and 
thus, there is a great need for novel alternative treatment therapies. The discovery of 
potential novel therapeutics for these disorders has been a major focal point for 
pharmaceutical research. The discovery of CRF, its analogs, and the identification and 
characterization of its receptors, have provided an overwhelming amount of insight into 
an organism’s response to stress. Even though such data have provided the necessary 
tools for the development of many functional peptide and non-peptide antagonist 
compounds, these have not resulted in any viable clinical candidates progressing beyond 
phase 2 clinical testing. In spite of this, there is still a great interest in understanding the 
relationship between CRF receptors and ligands. The increasing amount of data from 
observation of the discrete differences between CRF receptor subtypes and small 
molecules with potential therapeutic value is enabling the discovery of novel drugs for 
stress related disorders.  
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